ALK and non-small cell lung carcinoma: Patients with advanced non‐small cell lung cancer (NSCLC) harboring an anaplastic lymphoma kinase (ALK) rearrangement receive extended benefits from ALK tyrosine kinase inhibitors (TKIs).